Drug intelligence / Profile preview

yellow fever vaccine + Japanese encephalitis vaccine

Development stage
Unknown
Lead developer
Parent
Modality
Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

This combination refers to the co-administration or sequential use of the live-attenuated yellow fever vaccine (Stamaril) and the chimeric live-attenuated Japanese encephalitis vaccine (Imojev) in clinical research. Stamaril is a live-attenuated vaccine derived from the 17D strain of the yellow fever virus. Imojev is a recombinant chimeric vaccine that utilizes the YF-17D strain as a genetic backbone, expressing the pre-membrane and envelope proteins of the Japanese encephalitis virus. This specific combination was the subject of a Phase 2 clinical trial at Singapore General Hospital (SGH) titled "Cellular Immunity Correlates with YF17D and JE-YF17D Vaccines." The study aimed to determine if T-cell responses (CD4+ and CD8+) generated by the yellow fever vaccine backbone could reduce viremia upon challenge with the heterologous chimeric Japanese encephalitis vaccine, exploring the concept of cross-reactive cellular immunity between vaccines sharing a common vector backbone.

Brand names
StamarilYF-VAX
Other names
Stamaril + ImojevYF17D + JE-YF17D

Beyond the preview

Go deeper on yellow fever vaccine + Japanese encephalitis vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on yellow fever vaccine + Japanese encephalitis vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call